Insider Transactions in Q1 2026 at Becton Dickinson & CO (BDX)
Insider Transaction List (Q1 2026)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 27
2026
|
Carrie L Byington Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+17.95%
|
-
|
|
Jan 27
2026
|
R Andrew Eckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+9.53%
|
-
|
|
Jan 27
2026
|
Jeffrey William Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+10.72%
|
-
|
|
Jan 27
2026
|
Robert Luther Huffines Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+46.19%
|
-
|
|
Jan 27
2026
|
William M Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+19.06%
|
-
|
|
Jan 27
2026
|
Gregory Hayes Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+13.3%
|
-
|
|
Jan 27
2026
|
Bertram L Scott Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+2.83%
|
-
|
|
Jan 27
2026
|
Timothy M Ring Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+1.82%
|
-
|
|
Jan 27
2026
|
Christopher Ian Montague Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+4.32%
|
-
|
|
Jan 27
2026
|
Jacqueline Wright Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+46.19%
|
-
|
|
Jan 27
2026
|
Joanne Waldstreicher Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,098
+24.46%
|
-
|
|
Jan 26
2026
|
Michael Feld EVP, CRO & Pres. Life Sciences |
SELL
Open market or private sale
|
Direct |
75
-0.45%
|
$15,150
$202.73 P/Share
|
|
Jan 21
2026
|
Pamela L. Spikner SVP Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
84
-4.38%
|
-
|
|
Jan 15
2026
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Open market or private sale
|
Direct |
1,610
-6.04%
|
$333,270
$207.77 P/Share
|
|
Jan 15
2026
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,454
-15.19%
|
$512,886
$209.0 P/Share
|
|
Jan 15
2026
|
Michael David Garrison EVP & Pres Med.Essntl&BioPharm |
BUY
Exercise of conversion of derivative security
|
Direct |
3,054
+15.9%
|
$510,018
$167.91 P/Share
|
|
Jan 03
2026
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
44
-0.49%
|
-
|